Monitor upcoming quarterly earnings for clonoSEQ revenue growth and any updates on reimbursement expansion or NCCN guideline inclusion. The cure definition may drive increased testing volumes, but near-term financial impact is unquantified.
Price Chart
Executive Summary
Adaptive Biotechnologies announced a new consensus definition of cure for multiple myeloma, established by IMS and IMWG, which places sustained MRD negativity via next-generation sequencing at the center. The definition requires five years of complete remission with at least four negative MRD assessments at 10⁻⁶ sensitivity, positioning Adaptive's clonoSEQ assay as the only FDA-cleared NGS MRD test for this standard. This is a positive regulatory and commercial catalyst that could expand clonoSEQ's adoption in routine myeloma care, but no financial figures or guidance were provided.
Key Facts
- New consensus definition of cure for multiple myeloma requires five years in complete remission without treatment, with at least four negative MRD assessments at 10⁻⁶ sensitivity.
- clonoSEQ is the first and only FDA-cleared NGS MRD test for multiple myeloma and B-ALL (bone marrow) and CLL (blood or bone marrow).
- Definition was presented at IMS 23rd Annual Meeting on behalf of IMS and IMWG.
- No financial data, revenue, or guidance was provided in the press release.
Financial Impact
No financial figures provided; potential commercial expansion for clonoSEQ in multiple myeloma MRD testing.
Risk Factors
- No financial data or guidance provided; commercial impact is speculative.
- Adoption depends on clinician uptake and reimbursement; competitive MRD tests may emerge.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369095 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 144 | $26.28 | awaiting T+20 | — | $26.27 (−0.04%) |
Oct 5, 2026 20d ago | Insider Cluster | $26.90 | awaiting T+20 | — | $26.27 (−2.34%) |
Sep 25, 2026 4w ago | Press Release | $29.43 $25.51 | ▼ −13.32% | ▼ −11.84% | $26.27 (−10.74%) |
Sep 18, 2026 5w ago | Insider Cluster | $27.86 $23.95 | ▲ +14.03% | ▲ +13.13% | $26.27 (+5.71%) |
Aug 20, 2026 9w ago | Insider Cluster | $25.99 $27.86 | ▲ +7.20% | ▲ +7.72% | $26.27 (+1.08%) |
Aug 19, 2026 9w ago | Insider Cluster | $25.44 $28.55 | ▼ −12.22% | ▼ −12.22% | $26.27 (−3.26%) |
Aug 18, 2026 9w ago | 144 | $25.49 $26.68 | ▲ +4.67% | ▲ +6.19% | $26.27 (+3.06%) |
Aug 17, 2026 10w ago | 144 | $24.56 $27.67 | ▼ −12.66% | ▼ −13.97% | $26.27 (−6.96%) |
Jul 29, 2026 12w ago | Institutional Cluster | $24.18 $26.44 | ▼ −9.35% | ▼ −5.38% | $26.27 (−8.64%) |
Jul 23, 2026 13w ago | Insider Cluster | $22.27 $25.99 | ▲ +16.70% | ▲ +13.08% | $26.27 (+17.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers